Compound News and Research

RSS

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

6 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Researchers at Johns Hopkins have discovered that a compound in dark chocolate may protect the brain after a stroke by increasing cellular signals already known to shield nerve cells from damage.

6 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

New findings show seaweed extract inhibits H1N1 virus

In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Clinical development of RG7128 is on track: Pharmasset

Pharmasset, Inc., in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus in collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, stated today that the development of RG7128 is on track, and that no safety or other concerns have delayed the program.

4 May 2010

Pro-Pharmaceuticals closes $310,000 private placement tranche

Pro-Pharmaceuticals, Inc., today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Vanda reports total revenue of $12.4 million for first-quarter 2010

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2010.

4 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

Broccoli component sulforaphane targets and kills breast cancer stem cells

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells -- the small number of cells that fuel a tumor's growth -- according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

4 May 2010

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Compound News and Research

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

GENFIT announces milestone as compound developed in partnership enters the clinic

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

New breakthrough: Seaweed for treatment of swine flu

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

New findings show seaweed extract inhibits H1N1 virus

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Clinical development of RG7128 is on track: Pharmasset

Pro-Pharmaceuticals closes $310,000 private placement tranche

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Vanda reports total revenue of $12.4 million for first-quarter 2010

Natural plant extract could help treat COPD and inflammatory disorders

Broccoli component sulforaphane targets and kills breast cancer stem cells

TB Alliance, AstraZeneca sign research collaboration agreement to develop drugs against tuberculosis

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News